DOCSLIB.ORG

GCSG 2020 Global Virtual Conference Registrant List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
GCSG 2020 Global Virtual Conference Registrant List GCSG 2020 Global Virtual Conference Registrant List First Name Last Name Attendee company Attendee country Beth Adams Takeda United States Robert Adriaansen Berlinger & Co. AG Netherlands Christopher Allaire Clovis Oncology United States Deb Allwine Global Clinical Connections United States Alexi Anderson Regeneron United States David Antieau Zymeworks United States Kingsley Asam-Dankwah Bristol-Myers Squibb United States Andrew Atchley Arena Pharmaceuticals United States Steven Awad Johnson & Johnson United States Natalie Balanovsky Almac Group United States Jennifer Banh MyoKardia United States Jim Bannister Clinigen Group United States Lindsay Belcher Cryoport United States Melanie Bell SciLucent Inc. United States Harry Berlanga Thermofisher United Kingdom Sashin Bhuta Bristol-Myers Squibb United States Katie Bielat Apellis Pharmaceuticals United States William Birecree Bausch Health Companies United States Marcel Bizien VA Cooperative Studies Program United States Michelle Blandin Molecular Templates United States Alena Bolazeva Bristol Myers-Squibb Belgium Allen Bolden BDO USA, LLP (BPTG) United States Richard Bolnick Citation Healthcare Labels United States Bruce Bowman Marken Clinical Trial Logistics United States Caitlin Bowne Alkermes United States Ted Bradley Pfizer United States Tom Brady Xerimis United States Fadoua Braz Eli Lilly United States George Brennan ThermoFisher Scientific United States Lorna Briddick Brizzey United States William Brocious Eli Lilly United States Chris Brown QED Therapeutics United States Gerard Brown 4G Clinical United States Lisa Brown Mylan Pharmaceuticals United States Kimberly Buchanan Merck United States Andrew Buckley Takeda United States Jennifer Bulthuis Pfizer United States Cristine Burfeind United Therapeutics United States Kristi Byrnes Agios Pharmaceuticals United States Carolyn Cammarano Agios Pharmaceuticals United States Ana-Zeralda Canals Debiopharm International S.A. Switzerland GCSG 2020 Global Virtual Conference Registrant List First Name Last Name Attendee company Attendee country Orlando Casinio Arena Pharmaceuticals United States Barry Cathcart Almac Clinical Services United Kingdom Christine Chan Zymeworks United States Arjun Chandrashekar Pfizer Inc United States Cathy Cheney Ancillare, LLP United States Alex Chittim BAP US United States Andrea Chopek Client-Pharma United States Kenneth Christianson Recro United States Bryan Clayton YPrime United States Paula CLOZEL CREAPHARM CLINICAL SUPPLIES United States Mike Cohen Myoderm United States Kevin Collier Medidata Solutions United States Sandra Cook CookConsulting LLC United States Marla Cordova Astex Pharmaceuticals United States Greg Coulter CTM Solutions, LLC United States Adam Craig Pfizer United States Megan Crawford Astellas United States Patrick Crowley Alkermes United States Massimo Crudeli AX for Pharma United States Catherynne Cruz Scheckner Ionis United States Carla DA COSTA CREAPHARM CLINICAL SUPPLIES United States Amy Dailey Allergan United States Graig Daley Citation Healthcare Labels United States Rima Darwiche CPL Australia Australia Daniel David BioMarin Pharmaceutical Inc. United States Cristina Ann de Vera Inceptua United States Jason Dean Signant Health United States Jessica DeCarlo Bristol Myers Squibb United States (Magda) Elie Dechesne Bristol Myers Squibb Belgium Jennie Deem Eli Lilly and Company United States Monica DeKarski Moderna United States Laura Del Rossi Johnson & Johnson United States Jodi Dennis Mylan Pharmaceuticals United States Eric Deschamps Thermo Fisher Scientific United States Kristen DeVito Catalent United States Jay Dexheimer N-SIDE United States Paul Diercksen endpoint United States John Dillon Berlinger United States Tess Dineen BioMarin United States Tracie DiPasquale Acceleron Pharma United States Jeff Discenza Janssen United States GCSG 2020 Global Virtual Conference Registrant List First Name Last Name Attendee company Attendee country Therese Dolan Medidata United States Summer Doty Gossamer Bio United States J.B. Dowd Moderna United States Nicole Doyle AbbVie United States Alana Dreisbach Myoderm United States Rawle Dundas Alexion Pharmaceuticals, Inc United States Adam Duran N-SIDE United States Yasha Dwivedi Alkermes United States Judy Emmert Pfizer Inc. United States Lisa Erne Bausch & Lomb Inc United States Rhys Evans RxSource United Kingdom Tris Evans PCI Clinical Services United Kingdom Christine Fattore GCSG United States Brian Feehan Global BioPharm Solutions United States Hope Foudoulakis Agios Pharmaceuticals United States Michelle Foust Almac Group United States Neil Fox PCI Pharma Services United Kingdom Maud Fraiture Bristol Myers Squibb Belgium Jorge Franceschi TrialCard United States Alain Frix Eli Lilly and Company United States Jillian Fu Biogen United States Dan Fuller Bristol Myers Squibb United Kingdom Quibio Garcia Daiichi Sankyo, Inc. United States Jim Garlock Pfizer Inc United States Angela Geiger Gossamer Bio, Inc. United States Lisamarie Georgen MacroGenics, Inc. United States Chuck Gettis Suvoda United States Eveline Girod-Engelhardt CSL Behring United States Allison Girvan Agios United States Harresh Gobin Daiichi Sankyo, Inc. United States James Goebel Cold Chain Technologies United States Danielle Goodlett Neurocrine Biosciences Inc. United States Geetha Govindan Biogen United States Stephanie Graham Catalent Phama Soultions United Kingdom Nicole Gray Catalent United States Kathleen Greenough 4G Clinical United States Andrew Gregoire Myoderm United States Jessica Gregoire Myoderm United States Becky Griffiths PCI Clinical Services United Kingdom Ed Groleau PCI Clinical Services United States Levi Groner VAT IT United States GCSG 2020 Global Virtual Conference Registrant List First Name Last Name Attendee company Attendee country Kaitlin Guarasci Bay Area Research Logistics Canada Probir Gupta Aerie Pharmaceuticals United States Jill Hadley Sunovion irfan hafez Zymeworks Inc. Canada Michelle Hahn Eli Lilly and Company United States Karen Harrington Arena Pharmaceuticals United States Josh Hass AbbVie United States Ian Hassell Arena Pharmaceuticals United States Sarah-Jane Hayward PCI United Kingdom Steve Healy PHSE International United Kingdom Philip Heifetz Innovative Supply Solutions United States Christopher Hines 4G Clinical United States Ian Hoban Aposave United Kingdom Keith Hobson Halozyme Therapeutics United States Greg Hottell GSK United States Brian Huckabee Eli Lilly and Company United States Jeff Huminik VA Cooperative Studies Program United States Meridith Hyres Biogen United States Corinne Iacobucci Hookipa Pharma United States Joseph Iacobucci Moderna United States Terry Iacobucci GSK United States Giustina Ienna Bausch Health United States Mike Ikotun Y Prime United Kingdom Vincent Ioele Actinium Pharmaceuticals United States Sabrina Iqbal Jazz Pharmaceuticals United States Chalise Jackson Jazz Pharmaceuticals United States Steven Jacobs Global BioPharm Solutions United States Christy-Rae Jacobsen Sunovion United States David Jansen Eli Lilly and Company United States Britton Jimenez Catalent United States Mark Johnson Client-Pharma United States Diane Jones PTC Therapeutics United States Rob Jones Cryoport United States Sunday Kaerner Eli Lilly and Company United States Gary Kahn Aposave Denmark Christina Kalinowsky Sensitech Inc. United States JP Kappelle 4G Clinical Belgium Alison Kennedy Jazz Pharmaceuticals United States Rachel Kenny Heron Therapeutics United States Kelsey Kern CSL Behring, LLC United States Billie Key PCI Pharma Services United States GCSG 2020 Global Virtual Conference Registrant List First Name Last Name Attendee company Attendee country Jim Knapp Clinigen (CSM) United States Michael Koch Alkermes United States Stefanie Koleski Pfizer United States Julia Kong Vir Biotechnology Inc. United States Denise Lai Deciphera United States Craig LaMarca PCI Clinical Services United States Richard Lambie McKesson United Kingdom Ian Last Pfizer Quality United Kingdom Christine Lau Astex Pharmaceuticals United States Carol Lee Regeneron United States Sue Lee Hexagon Supply Chain United Kingdom Rachel Leong University of Georgia United States Mitchell LeSueur Daiichi Sankyo, Inc. United States Joyce Leung Arena Pharmaceuticals United States Si Li MCPHS United States Jennie Liblik Bristol Myers Squibb United Kingdom Alma Lincoln Alkermes United States Marc Lisi Suvoda United States Chan Liu Pfizer China James LoCascio Xerimis United States James Lovett Myoderm United States Becky Lubi Pfizer UK Jasmin Lucero Arena Pharmaceuticals United States Frank Lueddeke GCSG United States Dawn Lynn-Andrews Ionis Pharmaceuticals, Inc United States Doug MacVeigh CSL Behring United States Devin MaGrann endpoint clinical United States Kaitlyn Mandour Ionis Pharmaceuticals, Inc. United States Melita Marks Sensitech Inc. United States James Martin RegenXBio United States Chris Matheus Global Life Sciences Alliance United States Milan Mazzariello Regeneron United States Olive McCormick Almac Group United States Karen McNamara Infinity Pharmaceuticals, Inc. United States Jill McPartland Vila Otsuka United States Laurie McRae PAREXEL Shanelle Mehta BMclinical Netherlands Pearl Mensah Pilatus Comparator Solutions United States Doug Meyer Takeda United States Martin Mildenberger CSL Behring Germany Dave Mitchell The Leadership Difference United States GCSG 2020 Global Virtual Conference Registrant List First Name Last Name Attendee company Attendee country Ankita Modi Agios Pharmaceuticals United States Mike Mondo AeroSafe
Load more

Recommended publications
  • Updated May 26, 2021 Cross-Border Industry Partnerships on COVID-19 Vaccines and Therapeutics Vaccines • Curevac O Celonic Wi
    Updated May 26, 2021 Cross-Border Industry Partnerships on COVID-19 Vaccines and Therapeutics Vaccines • CureVac o Celonic will manufacture 100 million doses of CureVac’s vaccine at its plant in Heidelberg, Germany, providing bulk substance for 50 million doses by the end of 2021. (press release) o Novartis will manufacture CureVac’s vaccine. (press release) o GlaxoSmithKline plc and CureVac N.V. announced a new €150m collaboration, building on their existing relationship, to jointly develop next generation mRNA vaccines for COVID-19 with the potential for a multi-valent approach to address multiple emerging variants in one vaccine. (press release) o Rentschler Biopharma SE will manufacture CureVac’s vaccine. (press release) o Bayer will support the further development, supply and key territory operations of CureVac’s vaccine candidate. (press release) o Fareva will dedicate a manufacturing plant in France to the fill and finish of CureVac’s vaccine. (press release) o Wacker Chemie AG will manufacture CureVac’s vaccine candidate at its Amsterdam site. (press release) o CureVac will collaborate with Tesla Grohmann Automation to develop an RNA printer that works like a mini-factory and can produce such drugs automatically. (press release) • Moderna o Samsung Biologics will provide large scale, commercial fill-finish manufacturing for Moderna’s vaccine in South Korea. (press release) o Baxter International will provide fill/finish services and supply packaging for Moderna. (press release) o Sanofi will manufacture 200 million doses of Moderna’s COVID-19 vaccine starting in September 2021. (press release) o Rovi will produce bulk substance for Moderna’s COVID-19 vaccine, expanding an agreement between the companies.
    [Show full text]
  • Objectives & Accreditation
    Objectives & Accreditation ACTIVITY FORMAT Live TARGET AUDIENCE This activity is designed to meet the needs of physicians, physician assistants, pharmacists, registered nurses, nurse practitioners, advance practice registered nurses, and registered dietitians with an interest in lipid management. TYPE OF ACTIVITY Live Activity; Application/ Knowledge EDUCATIONAL OBJECTIVES At the conclusion of this activity, Registered Nurses and Nurse Practitioners should be able to provide appropriate care and counsel for patients and their families. At the conclusion of this activity, all participants should be able to: Session I: The Impact of Genetics in Lipidology? Apply insight from human population genetics studies to identify novel therapeutic targets for a better understanding for atherosclerotic cardiovascular disease. Describe the current and future technologies available for genetic screen includinghow to apply them in clinical practice both for diagnosis and risk assessment Discuss experimental techniques in development for genetic manipulation to target inherited lipid disorders Keynote I Discuss ApoC3 as both a risk factor for ASCVD and as potential for therapeutic manipulation Session II- Focus on Lipoprotein (a) Discuss the epidemiology of Lipoprotein(a) (LP(a)) for both thrombosis and ASCVD Discuss the pathophysiology of LP(a) and how this impacts increased risk of ASCVD and thrombosis Discuss the status of current and emerging treatment options targeting LP(a) Clinical Lipidology Track- Critically appraise emerging research
    [Show full text]
  • Final Attendee List
    Jennifer Abnet GlaxoSmithKline I GlaxoSmithKline I Jane Arboleda APRN Guardant I Molly Benson Sanjiv Agarwala MD Puma Biotechnology I Cancer Expert Now I Joe Arminger AbbVie I Seth Berkowitz LCSW, Manmeet Ahluwalia MD, CCLS MBA Patricia Armstrong The Leukemia & Lymphoma Miami Cancer Institute I Novartis I Society V Steve Albers Kim Arnold APRN CPNP Barry Berman MD, MS Alexion V CPHON Florida Cancer Specialists I Servier Pharmaceuticals I Maritza Alencar DNP, Tizano Bernard MBA, APRN, BMTCN Sheila Arrington MSN, Cancer Care Centers of Miami Cancer Institute V APRN, NP-C, AOCN Brevard I Puma Biotechnology I Carmen Allen MSIT Ana Mari Bernardini Pharmavoxx V Shannon Ashmon Novartis Oncology I Eisai, Inc I Luly Almeida Bernard Berry MBA Incyte Corporation I Sarah Ashton MS AstraZeneca Pharmaceuticals Guardant Health I I Talat Almukhtar MD Orlando Health Cancer Melissa Austin Jason Bever Institute I Cancer Care Centers of Oncopeptides I Brevard I Beatrice Alvarado Roberts Amy Bignon MD Garland Avera Doyle Caris Life Sciences I University of Florida I Jazz Pharmaceuticals I Nadeem Bilani MD Tadeu Ambros MD Francie Babcock Cleveland Clinic I FCS I AMAG Pharmaceuticals/Covis I Angela Bilik RN BSN Douglas Anderson AstraZeneca I Incyte Corporation I Craig Bailey Astra Zeneca I Jamie Bilsky BS Blesson Andrews Genentech V Genentech I Kevin Barr Daiichi Sankyo I Rohit Bishnoi MD Ollie Annum PharmD University of Florida I BHMCR I Leonard Bennett PharmD EMD Serono I Brady Blackman Susmitha Apuri MD MorphoSys I Florida Cancer Specialists I Michael Bennett As of 4-22-21 Kimberly Blandon RN MSN Rick Breitenstein Memorial Cancer Institute I Apellis Pharmaceuticals I Denise Capo Karyopharm Therapeutics I Taryn Boiteau GlaxoSmithKline I Amanda Bridges Florida Society of Clinical Heidi Caravetta Tracy Bonds RN, BSN, Oncology I Exelixis, Inc.
    [Show full text]
  • Pioneering New Markets Changing the Standard of Care
    ANNUAL 2020 REPORT Pioneering New Markets Changing the Standard of Care UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 □ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-19125 Ionis Pharmaceuticals, Inc. (Exact name of Registrant as specified in its charter) Delaware 33-0336973 (State or other jurisdiction of (IRS Employer incorporation or organization) Identification No.) 2855 Gazelle Court, Carlsbad, CA 92010 (Address of Principal Executive Offices) (Zip Code) 760-931-9200 (Registrant’s telephone number, including area code) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading symbol Name of each exchange on which registered Common Stock, $.001 Par Value ‘‘IONS’’ The Nasdaq Stock Market LLC Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark if the Registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☒ No □ Indicate by check if the Registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes □ No ☒ Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
    [Show full text]
  • Q1 Pharma Sector Snapshot
    SPECIALTY & GENERIC PHARMA Q1 2021 Report Market Commentary – Debt Capital Markets Debt Markets ▪ 2020 saw increased amounts of debt used in buyouts across the board, resulting in the highest debt / EBITDA Median US Buyout Multiples levels since 2014 − The increased use of debt was driven by 2H20 back- end loaded lending activity (primarily 4Q20) as 16.0x 12.7x 14.1x 12.2x 12.0x 11.6x 11.5x certainty around the U.S. election and vaccination 11.1x 10.0x 9.8x 12.0x 9.7x expectations increased 9.4x 8.6x 8.3x 8.2x 7.5x 7.8x 5.2x 6.7x 5.7x 5.6x ▪ 8.0x 5.9x As the effects of COVID now begin to diminish, debt 5.4x 4.4x 4.1x 3.7x 4.6x 4.3x 3.8x markets have seemingly recovered, signaling that 3.6x lenders have become increasingly comfortable with 4.0x 4.3x 6.9x 6.5x 6.3x 6.0x 5.9x 5.7x 5.7x 5.7x 5.7x 5.6x 5.3x 4.5x 4.4x macroeconomic and company-specific fundamentals 4.3x 0.0x 3.2x − With increased confidence, lenders are currently looking to provide strong leverage for high-quality assets, particularly ones that have proven their Debt/EBITDA Equity/EBITDA EV/EBITDA stability through the recent market downturn Source: PitchBook ▪ The spread on U.S. high-yield debt has returned to pre- Historical US High Yield Debt Effective Yield COVID levels − 4.22% current effective yield compared with a 12.0% 11.4% 11.38% effective yield on March 23, 2020 (peak of the pandemic) 9.0% ▪ We expect increased activity by lenders in 2021 due to: 6.0% 4.2% − Pent-up demand in M&A activity driven by the impact of COVID 3.0% − Limited Partner agreements and investor
    [Show full text]
  • Perrigo Needs Deal to Thwart Mylan
    November 02, 2015 Perrigo needs deal to thwart Mylan Madeleine Armstrong Perrigo continues to resist Mylan’s overtures, but a deal is looking increasingly likely after its attempts to block the buy in court failed. Mylan has until November 13 to tempt Perrigo shareholders under Irish takeover rules. An acquisition of its own might now be the only hope for Perrigo in this buy-or-be-bought saga. But, with increasing consolidation in the speciality pharma space, the pool of potential targets is dwindling (see table below). The best option looks like Endo International, though its market cap of nearly $14bn might make it too big a bite for Perrigo, which has just $5bn in cash. But if Perrigo could pull it off it would gain a company with one of the best forecast growth rates in mid-tier pharma. Jazz Pharmaceuticals, Meda or Lundbeck could be easier to digest but the last, with faltering sales, might not be such an attractive proposition. Perrigo and its potential acquisition targets Company Based Market cap ($bn) 2014 sales ($m) 2020e sales ($m) CAGR Perrigo Ireland 23.1 815 1,388 +9% Endo International US 13.6 2,053 5,616 +18% Jazz Pharmaceuticals Ireland 8.4 1,163 2,151 +11 Lundbeck Denmark 5.9 2,222 1,974 -2% Meda Sweden 5.4 1,963 2,519 +4% Last line of defence Perrigo’s chief executive, Joseph Papa, is standing firm but the company’s share price closed down 5% at $157.74 on Friday, well off its 2015 high of $203.69 in April after Mylan formalised its bid (Mylan anti-chain action as good as confirms Teva interest, April 09, 2015).
    [Show full text]
  • Generic Pharma
    SPECIALTY/GENERIC PHARMA SECTOR SNAPSHOT April 2019 Branded Specialty Pharma – Transaction Comps USD in millions Announced Geographic Enterprise EV / EV / Date Target Target Description Buyer Location Value LTM Revenue LTM EBITDA LTM Revenue LTM EBITDA Specialty pharmaceutical company focused in hospital InvaGen Nov-18 Avenue Therapeutics USA $210.2 NA NA NA NA products Pharmaceuticals Specialty pharmaceutical company focused in Oct-18 Corium International Gurnet Point Capital USA $492.5 $36.5 ($44.0) 13.5x NM transdermal and transmucosal products NextWave Specialty pharmaceutical company focused in Sep-18 Tris Pharma USA NA NA NA NA NA Pharmaceuticals pediatric CNS products Specialty pharmaceutical company focused in opioid Aug-18 Adapt Pharma Emergent BioSolutions Ireland $719.8 NA NA NA NA abuse products Sylvant from Johnson & Branded product for the treatment of Casteleman's Jul-18 EUSA Pharma Ireland $115.0 NA NA NA NA Johnson disease Femring in US from May-18 Branded women's health products Millicent Pharma USA $75.0 $23.0 $17.0 3.3x 4.4x Allergan Pancreaze from Johnson & Branded pancreatice enzyme replacement therapy May-18 VIVUS USA $135.0 $35.2 -- 3.8x -- Johnson product Specialty pharmaceutical company with focus across May-18 Willow Biopharma VIVUS Canada NA NA NA NA NA various therapeutic areas Large pharmaceuctical company with products across Apr-18 Shire Takeda Pharmaceutical Ireland $80,535.0 $15,354.0 $6,449.9 5.2x 12.5x a range of therapeutic areas and geographies Specialty pharmaceutical company focused on Feb-18 Altius
    [Show full text]
  • ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021
    ARK GENOMIC REVOLUTION MULTI SECTOR ETF (ARKG) HOLDINGS As of 09/27/2021 Company Ticker CUSIP Shares Market Value($) Weight(%) 1 TELADOC HEALTH INC TDOC 87918A105 3,937,797 531,208,815.30 6.99 2 EXACT SCIENCES CORP EXAS 30063P105 3,971,013 381,296,668.26 5.01 3 PACIFIC BIOSCIENCES OF CALIF PACB 69404D108 13,696,148 350,347,465.84 4.61 4 VERTEX PHARMACEUTICALS INC VRTX 92532F100 1,722,281 316,228,014.41 4.16 5 FATE THERAPEUTICS INC FATE 31189P102 4,825,395 312,926,865.75 4.12 6 IONIS PHARMACEUTICALS INC IONS 462222100 8,572,965 310,341,333.00 4.08 7 REGENERON PHARMACEUTICALS REGN 75886F107 430,742 275,201,063.80 3.62 8 TWIST BIOSCIENCE CORP TWST 90184D100 2,237,350 250,829,308.50 3.30 9 TAKEDA PHARMACEUTIC-SP ADR TAK UN 874060205 13,592,076 229,570,163.64 3.02 10 ACCOLADE INC ACCD 00437E102 5,268,242 226,850,500.52 2.98 11 INTELLIA THERAPEUTICS INC NTLA 45826J105 1,508,421 224,965,907.94 2.96 12 VEEVA SYSTEMS INC-CLASS A VEEV 922475108 741,198 222,307,516.14 2.92 13 CAREDX INC CDNA 14167L103 3,433,475 220,978,451.00 2.91 14 CRISPR THERAPEUTICS AG CRSP H17182108 1,804,041 210,044,493.63 2.76 15 INCYTE CORP INCY 45337C102 2,893,385 199,643,565.00 2.63 16 INVITAE CORP NVTA 46185L103 6,059,066 182,135,523.96 2.40 17 ADAPTIVE BIOTECHNOLOGIES ADPT 00650F109 4,888,391 178,377,387.59 2.35 18 BEAM THERAPEUTICS INC BEAM 07373V105 1,849,698 175,110,909.66 2.30 19 SIGNIFY HEALTH INC -CLASS A SGFY 82671G100 8,107,683 160,937,507.55 2.12 20 UIPATH INC - CLASS A PATH 90364P105 2,955,628 155,761,595.60 2.05 21 CASTLE BIOSCIENCES INC CSTL 14843C105 2,130,211
    [Show full text]
  • Management Team
    Management Team Bruce C. Cozadd Executive Chairman Bruce Cozadd joined Jazz Pharmaceuticals at its inception. From 2001 until he joined Jazz Pharmaceuticals, Mr. Cozadd served as a consultant to companies in the biopharmaceutical industry. From 1991 until 2001, he held various positions with ALZA Corporation, a pharmaceutical company now owned by Johnson & Johnson, most recently as its Executive Vice President and Chief Operating Officer, with responsibility for research and development, manufacturing and sales and marketing. Previously at ALZA Corporation he held the roles of Chief Financial Officer and Vice President, Corporate Planning and Analysis. Mr. Cozadd received a B.S. from Yale University and an M.B.A. from the Stanford Graduate School of Business. Mr. Cozadd serves on the boards of Cerus Corporation, a biopharmaceutical company; Threshold Pharmaceuticals, a biotechnology company; and The Nueva School and Stanford Hospital and Clinics, both non-profit organizations. Samuel R. Saks, MD Chief Executive Officer Samuel Saks, M.D., joined Jazz Pharmaceuticals at its inception. From 2001 until he joined Jazz Pharmaceuticals, Dr. Saks was Company Group Chairman of ALZA Corporation and served as a member of the Johnson & Johnson Pharmaceutical Group Operating Committee. From 1992 until 2001, he held various positions with ALZA Corporation, most recently as its Chief Medical Officer and Group Vice President, where he was responsible for clinical and commercial activities. Dr. Saks received a B.S. and an M.D. from the University of Illinois. Dr. Saks serves on the board of Trubion Pharmaceuticals and Cougar Biotechnology. Robert M. Myers President Robert Myers joined Jazz Pharmaceuticals at its inception and was appointed as Jazz Pharmaceuticals’ President in March 2007.
    [Show full text]
  • Medicaid System (Mmis) Illinois Department of Run Date: 08/08/2015 Provider Subsystem Healthcare and Family Services Run Time: 21:25:58 Report Id 2794D052 Page: 01
    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 08/08/2015 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 21:25:58 REPORT ID 2794D052 PAGE: 01 ALPHA COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 10/01/2015 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 68782 (OSI) EYETECH 65162 AMNEAL PHARMACEUTICALS LLC 00074 ABBOTT LABORATORIES 69238 AMNEAL PHARMACEUTICALS, LLC 68817 ABRAXIS BIOSCIENCE, LLC 53150 AMNEAL-AGILA, LLC 16729 ACCORD HEALTHCARE INCORPORATED 00548 AMPHASTAR PHARMACEUTICALS, INC. 42192 ACELLA PHARMACEUTICALS, LLC 66780 AMYLIN PHARMACEUTICALS, INC. 10144 ACORDA THERAPEUTICS, INC. 55724 ANACOR PHARMACEUTICALS 00472 ACTAVIS 10370 ANCHEN PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 62559 ANIP ACQUISITION COMPANY 45963 ACTAVIS INC. 54436 ANTARES PHARMA, INC. 46987 ACTAVIS KADIAN LLC 52609 APO-PHARMA USA, INC. 49687 ACTAVIS KADIAN LLC 60505 APOTEX CORP. 14550 ACTAVIS PHARMA MFGING PRIVATE LIMITED 63323 APP PHARMACEUTICALS, LLC. 67767 ACTAVIS SOUTH ATLANTIC 42865 APTALIS PHARMA US, INC 66215 ACTELION PHARMACEUTICALS U.S., INC. 58914 APTALIS PHARMA US, INC. 52244 ACTIENT PHARMACEUTICALS 13310 AR SCIENTIFIC, INC. 75989 ACTON PHARMACEUTICALS 08221 ARBOR PHARM IRELAND LIMITED 76431 AEGERION PHARMACEUTICALS, INC. 60631 ARBOR PHARMACEUTICALS IRELAND LIMITED 50102 AFAXYS, INC. 24338 ARBOR PHARMACEUTICALS, INC. 10572 AFFORDABLE PHARMACEUTICALS, LLC 59923 AREVA PHARMACEUTICALS 27241 AJANTA PHARMA LIMITED 76189 ARIAD PHARMACEUTICALS, INC. 17478 AKORN INC 24486 ARISTOS PHARMACEUTICALS, INC. 24090 AKRIMAX PHARMACEUTICALS LLC 67877 ASCEND LABORATORIES, L.L.C. 68220 ALAVEN PHARMACEUTICAL, LLC 76388 ASPEN GLOBAL INC. 00065 ALCON LABORATORIES, INC. 51248 ASTELLAS 00998 ALCON LABORATORIES, INC. 00469 ASTELLAS PHARMA US, INC. 25682 ALEXION PHARMACEUTICALS 00186 ASTRAZENECA LP 68611 ALIMERA SCIENCES, INC.
    [Show full text]
  • Current Sustaining Member Companies
    CURRENT SUSTAINING MEMBER COMPANIES MEMBER FOR OVER: 10 Years 25 Years 50 Years Member Since (alphabetical order) 1976 3M Medical Solutions Division 2020 D2 Pharma Consulting, LLC 1989 J & J Health Care Systems, Inc. 2011 Remund Group, LLC 1985 Abbott Laboratories, Inc. 2007 Daiichi Sankyo, Inc. 2014 Jazz Pharmaceuticals Inc. 2018 Rigel Pharmaceuticals 2013 AbbVie Inc. 2020 Deciphera Pharmaceuticals, LLC 2007 Karl Storz Endoscopy America 2000 Sanofi 2021 Adaptive Biotechnologies 2009 Deloitte 2021 Lantheus Holdings 2020 Seattle Genetics 2017 ACADIA Pharmaceuticals, Inc. 2020 Dexcom, Inc. 2020 Lipogems 2004 Siemens Medical Solutions 2020 AcelRx Pharmaceuticals, Inc. 2020 Drip Drop Hydration 2010 LLC Federal Solutions 2019 SK Life Science, Inc. 2020 Acorda Therapeutics 2017 Eagle Pharmaceuticals, Inc. 2014 Lovell Government Services LLC 2002 Smith & Nephew, Inc. 2019 Aimmune 2005 Eisai, Inc. 2021 Mainstay Medical 2019 Sobi Inc. 2003 Alcon Laboratories, Inc. 2019 electroCore, Inc. 2014 Mallinckrodt Pharmaceuticals 2013 Stryker Orthopaedics 2019 Alexion Pharmaceuticals, Inc. 2010 Endo Pharmaceuticals 2020 MannKind Corporation 2018 Sun Pharmaceutical 2017 Alkermes, Inc. 2017 Exelixis 1999 Marketing Assessment, Inc. 1999 Sunovion Pharmaceuticals, Inc. 2019 Alnylam Pharmaceuticals 2016 Express Scripts Federal Pharmacy 2009 Masimo Corporation 2016 Taiho Oncology, Inc. 2019 Altarum Institute 2010 Federal Practitioner 2019 Medical Strategies International, LLC 2015 Takeda Oncology 2020 Amarin Corporation 2021 Ferring Pharmaceuticals Inc. 2016 Melling Medical 2000 Takeda Pharmaceutical USA, Inc. 1994 AmerisourceBergen 2018 Foundation Medicine, Inc. 1954 Merck & Co., Inc. 2020 Telemynd 1992 Amgen 2021 Frontier Technology Inc. (FTI) 2002 MerzNorth America 2020 TerSera Therapeutics 2020 Amneal Pharmaceutical 2020 Fresenius Medical Care North America 2018 Mitsubishi Tanabe Pharma America 1990 Teva 2019 Aptive Resources LLC 1989 Genentech Inc.
    [Show full text]
  • October 2019
    J.P. Morgan Healthcare Conference Presented by Brett P. Monia, Ph.D. Chief Executive Officer January 15, 2020 Forward Looking Language Statement This presentation includes forward-looking statements regarding our business, financial guidance and the therapeutic and commercial potential of SPINRAZA® (nusinersen), TEGSEDI™ (inotersen), WAYLIVRA™ (volanesorsen) and Ionis' technologies and products in development, including the business of Akcea Therapeutics, Inc., Ionis' majority owned affiliate. Any statement describing Ionis’ goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines. Ionis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2018, and its most recent Form 10-Q quarterly filing, which are on file with the SEC. Copies of this and other documents are available at www.ionispharma.com. In this presentation, unless the context requires otherwise, “Ionis,” “Company,” “we,” “our,” and “us” refers to Ionis Pharmaceuticals and its subsidiaries.
    [Show full text]